Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

2.459 -0.001 (-0.04%)

Streaming Delayed Price Updated: 10:16 AM EDT, Aug 21, 2026 Add to My Watchlist

Price and Volume

Volume	350,179
Open	2.470
Bid (Size)	2.450 (2,200)
Ask (Size)	2.460 (1,100)
Prev. Close	2.460
Today's Range	2.400 - 2.510
52wk Range	1.175 - 2.580
Shares Outstanding	52,346,231
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Autolus (AUTL) Q2 2026 Earnings Call Transcript ↗

August 18, 2026

Revenue surged 119% year-over-year as gross margins turned positive for the first time.

Via The Motley Fool

Autolus Therapeutics Q2 Earnings Call Highlights ↗

August 11, 2026

Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier,...

Via MarketBeat

Performance

YTD	+31.5%	+31.5%
1 Month	+67.8%	+67.8%
3 Month	+49.0%	+49.0%
6 Month	+49.9%	+49.9%
1 Year	+42.1%	+42.1%

More News

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

August 11, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics (NASDAQ:AUTL) Posts Inline Q1 Results with First Positive Gross Margin, but Full-Year Guidance Slightly Below Consensus ↗

May 14, 2026

Via Chartmill

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

August 03, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Top stock movements in today's session. ↗

August 03, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 03, 2026

Via Chartmill

Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors

August 03, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 01, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conference

June 25, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Receives Prix Galien UK Award

June 12, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

May 27, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

May 21, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus (AUTL) Q1 2026 Earnings Transcript ↗

May 18, 2026

Via The Motley Fool

Autolus Therapeutics Q1 Earnings Call Highlights ↗

May 14, 2026

Via MarketBeat

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 14, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

May 05, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

April 29, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector

April 22, 2026

Via Investor Brand Network

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

April 22, 2026

Via Investor Brand Network

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 21, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

April 07, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

April 22, 2026

From BioMedWire

Via GlobeNewswire

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

March 27, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

March 16, 2026

From Autolus Therapeutics plc

Via GlobeNewswire

Frequently Asked Questions

Is Autolus Therapeutics plc - American Depositary Shares publicly traded?

Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.

What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?

Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?

The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market

What is the current price of Autolus Therapeutics plc - American Depositary Shares?

The current price of Autolus Therapeutics plc - American Depositary Shares is 2.459

When was Autolus Therapeutics plc - American Depositary Shares last traded?

The last trade of Autolus Therapeutics plc - American Depositary Shares was at 08/21/26 10:16 AM ET

What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?

The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 128.72M

How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?

Autolus Therapeutics plc - American Depositary Shares has 129M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.